{"id":126276,"date":"2025-05-22T16:17:31","date_gmt":"2025-05-22T15:17:31","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"},"modified":"2025-05-22T16:17:31","modified_gmt":"2025-05-22T15:17:31","slug":"el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","title":{"rendered":"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \u00abTofersen\u00bb, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA"},"content":{"rendered":"

\u2022 La Comisi\u00f3n Interministerial de Precios de los
\nMedicamentos (CIPM) ha aprobado la financiaci\u00f3n de Tofersen,
\nun tratamiento innovador comercializado bajo el nombre de Qalsody
\n\u00ae. Espa\u00f1a es uno de los primeros pa\u00edses europeos
\nen hacerlo.\u00a0<\/p>\n

\u2022 Se trata de un medicamento hu\u00e9rfano al que la
\nAgencia Europea del Medicamento (EMA) ha concedido
\nautorizaci\u00f3n bajo \u201ccircunstancias excepcionales\u201d
\ndebido a la rareza de la enfermedad y a la limitada disponibilidad
\nde datos cl\u00ednicos.\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

\u2022 La Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM) ha aprobado la financiaci\u00f3n de Tofersen, un tratamiento innovador comercializado bajo el nombre de Qalsody \u00ae. Espa\u00f1a es uno de los primeros pa\u00edses europeos en hacerlo.\u00a0 \u2022 Se trata de un medicamento hu\u00e9rfano al que la Agencia Europea del Medicamento (EMA) ha concedido autorizaci\u00f3n bajo […]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-126276","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"\nEl Ministerio de Sanidad aprueba la financiaci\u00f3n de "Tofersen", primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El Ministerio de Sanidad aprueba la financiaci\u00f3n de "Tofersen", primer tratamiento dirigido a una causa gen\u00e9tica de la ELA\" \/>\n<meta property=\"og:description\" content=\"\u2022 La Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM) ha aprobado la financiaci\u00f3n de Tofersen, un tratamiento innovador comercializado bajo el nombre de Qalsody \u00ae. Espa\u00f1a es uno de los primeros pa\u00edses europeos en hacerlo.\u00a0 \u2022 Se trata de un medicamento hu\u00e9rfano al que la Agencia Europea del Medicamento (EMA) ha concedido autorizaci\u00f3n bajo […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-22T15:17:31+00:00\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \u00abTofersen\u00bb, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA\",\"datePublished\":\"2025-05-22T15:17:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\"},\"wordCount\":97,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\",\"name\":\"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \\\"Tofersen\\\", primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"datePublished\":\"2025-05-22T15:17:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \u00abTofersen\u00bb, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \"Tofersen\", primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","og_locale":"es_ES","og_type":"article","og_title":"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \"Tofersen\", primer tratamiento dirigido a una causa gen\u00e9tica de la ELA","og_description":"\u2022 La Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM) ha aprobado la financiaci\u00f3n de Tofersen, un tratamiento innovador comercializado bajo el nombre de Qalsody \u00ae. Espa\u00f1a es uno de los primeros pa\u00edses europeos en hacerlo.\u00a0 \u2022 Se trata de un medicamento hu\u00e9rfano al que la Agencia Europea del Medicamento (EMA) ha concedido autorizaci\u00f3n bajo […]","og_url":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","og_site_name":"bip4ex","article_published_time":"2025-05-22T15:17:31+00:00","author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \u00abTofersen\u00bb, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA","datePublished":"2025-05-22T15:17:31+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"},"wordCount":97,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","url":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/","name":"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \"Tofersen\", primer tratamiento dirigido a una causa gen\u00e9tica de la ELA - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"datePublished":"2025-05-22T15:17:31+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/el-ministerio-de-sanidad-aprueba-la-financiacion-de-tofersen-primer-tratamiento-dirigido-a-una-causa-genetica-de-la-ela\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"El Ministerio de Sanidad aprueba la financiaci\u00f3n de \u00abTofersen\u00bb, primer tratamiento dirigido a una causa gen\u00e9tica de la ELA"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/126276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=126276"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/126276\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=126276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=126276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=126276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}